- Companies
- Glooko
Glooko Valuation, Funding & Investors
Glooko is valued at $476M as of October 2024.
Last Glooko valuation
$476M
Series F · Oct 2024
Last Glooko funding round
$100M
Series F · Oct 2024
Cumulative funding Glooko raised
$197M
across 6 funding rounds
Key investors in Glooko
Canaan Partners
Social Capital
Samsung NEXT
Georgian
Mayo Clinic
Medtronic
About Glooko
Glooko is a Mountain View-headquartered remote patient monitoring platform for diabetes management. It syncs data from devices like Dexcom G7, Omnipod pumps, and Fitbit trackers into a cloud dashboard for clinicians. Available on iOS and Android, Glooko generates reports shared via telehealth. Launched in 2010, it supports 4 million users and partners with insurers like UnitedHealthcare.
Founded
2010
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Valuation
$476M (Oct 2024)
Glooko Valuation
Glooko is currently valued at $476M, based on its Series F in October 2024.
The $100M round was led by Georgian, with participation from Canaan Partners and Health Catalyst Capital.
Glooko valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Oct 2024 | Series F | $476M |
Glooko Funding History
Glooko has raised a total of $197M across 6 funding rounds.
Glooko's first fundraising round was a $7M Series A in January 2014. The most recent completed round was a $100M Series F in October 2024.
Glooko funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Oct 2024 | Series F | Georgian (lead); Canaan Partners; Health Catalyst Capital | $100M | $476M | Glooko is a leading digital health platform for remote patient monitoring and chronic care management, particularly focused on diabetes and obesity management. The company operates a device-agnostic platform that aggregates data from medical devices and connected systems, serving clinicians, healthcare facilities, health insurance plans, employers, and pharmaceutical companies across North America and expanding into the Middle East and Asia. In October 2024, Glooko secured $100 million in Series F funding led by Georgian, with participation from existing investors Canaan Partners, Health Catalyst Capital, and other business partners. The company appointed Mike Alvarez as CEO in connection with this round; Alvarez came from Qardio and previously held leadership roles at Medtronic, Sanofi, and St. Jude Medical. At the time of the Series F funding, Glooko reported monitoring approximately 10,000 clinics and over one million diabetes patients, establishing itself as the largest aggregator of diabetes data in the United States. The company has demonstrated sustained growth despite the shift in the digital health investment landscape, with investors emphasizing its sound business plan and consistent revenue growth. Glooko has expanded through acquisitions, including xbird (a Berlin-based health AI company) in 2022 and DIABNEXT (a Paris-based digital health platform) in the same year, strengthening its capabilities in adaptive intervention technologies and patient engagement. |
| Mar 2021 | Series D | Health Catalyst Capital (lead); Novo Nordisk; Canaan Partners; Georgian; Insulet; Mayo Clinic | $30M | - | Glooko Inc. is a leading provider of remote patient monitoring and chronic care management solutions, focusing on diabetes and obesity. On March 16, 2021, it raised a $30 million Series D financing round led by Health Catalyst Capital, with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet, and Mayo Clinic. The proceeds were intended to accelerate organic growth and strategic initiatives across its product line of advanced digital health solutions, including increasing adoption of its remote patient monitoring platform, widening commercialization in clinical research, and expanding into additional therapy areas. The round reflected Glooko's increasing trajectory and market growth, following a successful 2020 despite the global pandemic. That year, the company expanded partnerships with major healthcare systems and extended long-term collaborations with global diabetes leaders like Insulet and Novo Nordisk. By then, Glooko had grown its global ecosystem to more than 7,500 clinics and partnered with many of the world's largest diabetes medical device companies, pharmaceutical companies, and top healthcare systems. Health Catalyst Capital's investment was driven by Glooko's cutting-edge digital healthcare platforms that empower diabetes patients to manage their disease better and enable physicians to enhance patient care through stronger engagement. |
| Jun 2017 | Series C | Georgian (lead); Samsung NEXT; Canaan Partners; Medtronic; Social Capital; Insulet; Mayo Clinic | $35M | - | Glooko is a diabetes management platform that provides a device-agnostic data management service enabling doctors to remotely monitor patients with diabetes. The company raised $35 million in a Series C funding round on June 28, 2017, led by Georgian Partners, with participation from new investors Insulet Corporation and Mayo Clinic, alongside existing backers Canaan Partners, Social Capital, Medtronic, and Samsung Next. This brought Glooko's total funding to $71 million after prior raises of $36 million. At the time of the round, Glooko reported serving more than 1 million patients through over 6,000 providers. The funding was earmarked for expanding sales, marketing, and development teams, as well as commercialization efforts in France, Germany, the U.K., Asia, and the Middle East. CEO Rick Altinger emphasized accelerating investments in clinical solutions to boost medication adherence, deliver personalized insights, drive behavior change, and provide clinical decision support to clinicians between patient visits. Glooko operates in a competitive diabetes management space against larger players like Dexcom and Medtronic, necessitating rapid expansion to maintain momentum. |
| Sep 2016 | Series C | Canaan Partners (lead); Samsung NEXT; Social Capital; Yogen Dalal | $8M | - | Glooko is a diabetes management platform based in Palo Alto, California. It raised $16.5 million in a Series B round led by Canaan Partners, which also included participation from Medtronic. This followed a seed round in 2011. Subsequent rounds included a Series C-Prime on 09/17/2016 and a $35 million Series C in June 2017 led by Georgian Partners with Canaan Partners, Social Capital, Samsung NEXT, Insulet, and Mayo Clinic. A $30 million Series D followed in March 2021 led by Health Catalyst Capital. |
| Mar 2015 | Series B | Canaan Partners (lead); Medtronic (lead); Samsung NEXT; Social Capital | $17M | - | Glooko is a healthcare software company based in Palo Alto, California that provides a personalized, intelligent, connected care platform for people with chronic conditions. The platform revolutionizes the connection between patients and providers through digital therapeutics and patient engagement solutions, and supports the acceleration of clinical trials. In 2015, Glooko raised $16.5 million in Series B funding. The company has raised a total of $190.5 million across seven funding rounds to date. |
| Jan 2014 | Series A | Samsung NEXT; Sunny Madra; Glooko; Social Capital | $7M | - | Glooko is an FDA-cleared mobile diabetes management system enabling clinicians to remotely access patients' blood glucose readings and related data. The company's platform includes a mobile app, MeterSync Cable for iOS and Android, and a Web Dashboard. In January 2014, Glooko raised $7 million in Series A-1 funding led by Samsung Venture Investment Company (SVIC) and Lifeforce Ventures, with participation from existing investors including Social+Capital Partnership, Sundeep Madra, and Yogen Dalal. The capital was directed toward enabling predictive diabetes care by delivering patient data and decision-making algorithms to health providers and payer groups, as well as scaling the system to global accessibility and adding analytics capabilities for therapeutic recommendations. |
Who has invested in Glooko?
12 investors have backed Glooko across its funding rounds, including Canaan Partners, Social Capital, Samsung NEXT, Georgian, Mayo Clinic and Medtronic.
Lead investors include Georgian, Health Catalyst Capital, Canaan Partners and Medtronic.
Glooko Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 5 | Lead | Mar 2015 | ||
| 4 | Participant | Jan 2014 | ||
| 4 | Participant | Jan 2014 | ||
| 3 | Lead | Jun 2017 | ||
| 2 | Lead | Mar 2015 | ||
| 2 | Lead | Mar 2021 | ||
| 2 | Participant | Jun 2017 | ||
| 2 | Participant | Jun 2017 | ||
| 1 | Participant | Mar 2021 | ||
| 1 | Participant | Jan 2014 | ||
This data is available for Pro users. Sign up to see all 12 Glooko investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Glooko
Glooko has acquired 4 companies to date.
Last acquisition by Glooko was on September 23rd 2025. Glooko acquired Monarch Medical Technologies for undisclosed valuation.
Latest Acquisitions by Glooko
| Description | Monarch Medical Technologies is a Charlotte-based digital health company offering the FDA-cleared EndoTool Glucose Management System. The software automates insulin dosing for hospitalized patients, integrating with EMRs like Epic and Cerner. Deployed in over 100 U.S. hospitals, EndoTool supports critical and non-critical care settings to optimize glycemic control. | Diabnext is a Paris-based digital health company offering an automated insulin and glucose monitoring system combining a smart cap for pens with a mobile app. The device scans barcodes on insulin cartridges and vials, logging doses alongside CGM data for real-time analysis and sharing with clinicians. Launched in 2020, it integrates with Apple Health and supports therapeutic education modules for over 10,000 users in France. | Xbird is a Berlin-headquartered healthcare software firm founded in 2015 that applies AI to diabetes management. Its platform analyzes data from smartphones and wearables to predict glucose fluctuations and personalize insulin dosing for patients. Integrated with devices from Dexcom and Abbott, the service supports holistic therapy in clinics across Germany and expands to cardiovascular risk monitoring. | Diasend is a Gothenburg-headquartered diabetes management platform operating in 23 countries with subsidiaries in Chicago and London. The service aggregates data from 140 glucose meters, insulin pumps, CGMs like Dexcom, and activity trackers into a shared dashboard for patients and clinicians. All components carry FDA clearance and CE marking. Diasend transmits over 1 billion data points yearly, enabling remote monitoring and HbA1c trend analysis. Founded in 2007, it integrates with electronic health records in Sweden and the UK. |
| HQ Country | ||||
| HQ City | Charlotte, NC | Paris | Berlin | Chicago, IL |
| Deal Date | 23 Sep 2025 | 16 Mar 2022 | 31 Jan 2022 | 13 Sep 2016 |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Glooko acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Glooko Competitors
Glooko competitors include listed companies like DarioHealth and Yidu Tech, and private ones like Well, Viome, Biopeak and Evidation Health.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $450M | - | ||
| Private | - | - | $339M | - | ||
| Private | $2M | - | $250M | 125.0x | ||
| Private | - | - | $1B | - | ||
| Publicly listed | $22M | ($36M) | $69M | 4.0x | ||
| Publicly listed | $122M | ($4M) | $449M | 1.2x |
Glooko Public Comps
Glooko is still privately-owned, but its public comps include Bayzed Health Group, Yidu Tech, TaiDoc Technology, Veradigm, Evolent Health, Cogstate, Echo IQ, SOPHiA Genetics, Nyxoah and Ever Fortune.AI.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $167M | $18M | 3.0x | - | 28.4x | - | |||
| $122M | ($4M) | 1.4x | 1.2x | (45.0x) | 7.7x | |||
| $132M | $58M | 2.1x | - | 4.8x | - | |||
| $588M | $54M | 0.9x | 0.9x | 9.8x | 6.8x | |||
| $1.9B | ($365M) | 0.7x | 0.5x | (3.5x) | 9.4x | |||
| $58M | $18M | 6.3x | 5.7x | 20.0x | 18.9x | |||
| $65K | ($13M) | 4656.6x | 994.2x | (23.1x) | (26.6x) | |||
| $77M | ($65M) | 8.8x | 7.5x | (10.4x) | (18.8x) | |||
This data is available for Pro users. Sign up to see all Glooko competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Glooko
| When was Glooko founded? | Glooko was founded in 2010. |
| Where is Glooko headquartered? | Glooko is headquartered in San Francisco, CA, United States. |
| Is Glooko publicly listed? | No, Glooko is a private, VC-backed company. |
| What is Glooko's valuation? | Glooko was last valued at $476M in its Series F in October 2024. |
| How much funding has Glooko raised? | Glooko has raised $197M across 6 funding rounds. |
| What was Glooko's last funding round? | Glooko's last funding round was a $100M Series F in October 2024, led by Georgian. |
| Who are Glooko's investors? | Glooko's investors include Canaan Partners, Samsung NEXT, Social Capital, Georgian, Medtronic, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk, Sunny Madra and 2 others. |
| Which companies are comparable to Glooko? | Companies comparable to Glooko include Well, Viome, Biopeak, Evidation Health, DarioHealth and Yidu Tech. |
| How many companies has Glooko acquired? | Glooko has acquired 4 companies, including Monarch Medical Technologies, Diabnext, Xbird and Diasend. |
See companies similar to Glooko
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




